2025-04-09 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

This report analyzes Johnson & Johnson (JNJ), a multinational healthcare corporation, based on the provided data.

**1. Performance Comparison & Alpha/Beta Analysis:**

JNJ's cumulative return (24.15%) significantly underperformed the S&P 500 (VOO) which returned 55.66%. The difference is -31.5%, placing it at the 47.8th percentile of historical underperformance relative to the S&P 500 based on the provided min/max range.

The provided Alpha/Beta analysis shows mixed performance over various periods. While some periods exhibit positive alpha (outperformance relative to the market), recent years show negative CAGR and a consistently low alpha, suggesting underperformance against the market benchmark. Beta remains relatively low and stable, indicating lower volatility than the market.  The significant market cap consistently remains high.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 28.0% | 56.0% | -1.0% | 0.0 | 275.3 |
| 2016-2018  | 10.0% | 10.8% | -7.0% | 0.0 | 261.2 |
| 2017-2019  | 20.0% | 10.8% | -9.0% | 0.7 | 303.6 |
| 2018-2020  | 14.0% | 59.8% | -12.0% | 0.5 | 336.4 |
| 2019-2021  | 28.0% | 59.9% | -26.0% | 0.3 | 374.9 |
| 2020-2022  | 4.0% | 61.2% | -2.0% | 0.3 | 397.3 |
| 2021-2023  | -19.0% | 61.2% | -35.0% | 0.4 | 363.2 |
| 2022-2024  | -31.0% | 61.2% | -47.0% | 0.3 | 345.7 |
| 2023-2025  | -2.0% | 69.6% | -5.0% | 0.2 | 363.7 |


**2. Recent Price Movement:**

* **Closing Price:** $150.93
* **Last Market Price:** $150.81 (Slight increase of $0.12 from the previous close)
* **5-Day Moving Average:** $154.52
* **20-Day Moving Average:** $161.13
* **60-Day Moving Average:** $156.84

The stock price is currently trading below all three moving averages, suggesting a possible downtrend.

**3. Technical Indicators & Expected Return:**

* **Market Risk Indicator (MRI):** 0.4883 (High Risk) indicating increased market volatility.
* **RSI:** 32.18 (Below 30, suggesting oversold conditions)
* **PPO:** -0.96 (Negative value, indicating bearish momentum)
* **Relative Strength Change (20-day):** +14.9 (Short-term upward momentum)
* **Expected Return:** -30.9% (Significant negative expected return relative to the S&P 500 over the long term - 2 years or more)  This suggests significant underperformance is expected even over the long term.  The small price increase is not reflected in the long term expectation.

**4. Recent Earnings Analysis:**

| Date       | EPS   | Revenue        |
|------------|-------|----------------|
| 2024-10-23 | 1.12  | $22.47 B       |
| 2024-07-25 | 1.95  | $22.45 B       |
| 2024-05-01 | 1.35  | $21.38 B       |
| 2024-02-16 | 1.68  | $21.39 B       |
| 2023-10-27 | 10.32 | $21.35 B       |

EPS shows significant volatility, with a substantial drop in the most recent quarter (Oct 2024). Revenue remains relatively stable.  The October 2023 EPS is exceptionally high compared to the other values provided, suggesting a possible anomaly that warrants further investigation.

**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue    | Profit Margin |
|---------|------------|---------------|
| 2024-12-31 | $22.52B   | 68.35%        |
| 2024-09-30 | $22.47B   | 69.01%        |
| 2024-06-30 | $22.45B   | 69.40%        |
| 2024-03-31 | $21.38B   | 69.55%        |
| 2023-12-31 | $21.39B   | 68.23%        |

Revenue is relatively consistent. Profit margins remain high and stable, indicating strong profitability.

**Capital and Profitability:**

| Quarter | Equity      | ROE     |
|---------|-------------|---------|
| 2024-12-31 | $71.49B    | 4.80%   |
| 2024-09-30 | $70.16B    | 3.84%   |
| 2024-06-30 | $71.54B    | 6.55%   |
| 2024-03-31 | $70.02B    | 4.65%   |
| 2023-12-31 | $68.77B    | 5.89%   |

Equity fluctuates slightly. ROE shows some variability but remains generally positive.


**6. Overall Conclusion:**

JNJ has consistently underperformed the S&P 500 in recent years, as reflected in the negative alpha and CAGR. While the company maintains strong profitability and a large market cap, the recent price action and technical indicators suggest a bearish outlook.  The significantly negative expected return strongly suggests against investment in JNJ relative to the S&P 500.  The exceptionally high EPS value for October 2023 needs further investigation to determine if this is an anomaly or a data issue.  Further research into the reasons behind the recent underperformance and the drop in EPS is crucial before making any investment decisions.  The current data does not support JNJ investment relative to the market.
